$HLVX News
Last published 1y ago
- 1y agoHLVXXOMAXOMAOXOMAPXOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.GlobeNewswireEMERYVILLE, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech
- 1y agoHLVXHilleVax Reports Second Quarter 2025 Financial ResultsGlobeNewswireBOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the
- 1y agoHLVXXOMAXOMAOXOMAPHilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value RightGlobeNewswireBOSTON and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) and XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) announced today they have entered
- 1y agoHLVXHilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressGlobeNewswire$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business
- 1y agoHLVXPHATFrazier Life Sciences Appoints Aditya Kohli to PartnerBusiness WireFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a
- 1y agoHLVXHilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company ProgressGlobeNewswire$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as
- 2y agoHLVXHilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewswire$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as
- 2y agoHLVXHilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewswire$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults
- 2y agoHLVXHilleVax Announces Reduction in ForceGlobeNewswireBOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to
- 2y agoHLVXHilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in InfantsGlobeNewswireThe NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential for continued
- 2y agoHLVXHilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewswireTopline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE
- 2y agoHLVXHilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswireTopline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable
- 2y agoHLVXHilleVax to Present at Guggenheim 6th Annual Biotechnology ConferenceGlobeNewswireBOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the
- 2y agoHLVXHilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating OfficerGlobeNewswireBOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean
- 2y agoHLVXHilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of ChinaGlobeNewswireBOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu Kanghua
- 2y agoHLVXHilleVax to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the
- 3y agoHLVXHilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswireBOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the
- 3y agoHLVXHilleVax to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the
- 3y agoHLVXHilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare ConferenceGlobeNewswireBOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the
- 3y agoHLVXHilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has closed its
- 3y agoHLVXHilleVax Announces Pricing of Public Offering of Common StockGlobeNewswireBOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its public
- 3y agoHLVXHilleVax Announces Proposed Public Offering of Common StockGlobeNewswireBOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and
- 3y agoHLVXHilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswireBOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the
- 3y agoHLVXHilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewswireBOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the
- 3y agoHLVXHilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of DirectorsGlobeNewswireBOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Nanette
- 3y agoHLVXHilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine CandidateGlobeNewswireTopline safety and clinical efficacy data from NEST-IN1 expected in the first quarter of 2024 HIL-214 is the most advanced vaccine candidate for norovirus infection There are currently no approved vaccines for
- 3y agoHLVXHilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswireBOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the
- 3y agoHLVXHilleVax Announces Executive Management Appointments and PromotionsGlobeNewswireBOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Ozzie
- 3y agoHLVXHilleVax to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the
- 3y agoHLVXHilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine CandidateGlobeNewswireBOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified
- 4y agoHLVXHilleVax to Participate in November Investor ConferencesGlobeNewswireBOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in
- 4y agoHLVXHilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswireBOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the
- 4y agoHLVXHilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call SeriesGlobeNewswireBOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Co
- 4y agoHLVXHilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine CandidateGlobeNewswireEnrollment of remaining subjects in NEST-IN1 has resumed Immunogenicity results from the first 200 subjects expected in Q4 2022 BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical com
- 4y agoHLVXHilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine ForumGlobeNewswireBOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in a fireside chat during the SVB Secu
- 4y agoHLVXHilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswireBOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2022, highlight
- 4y agoHLVXHilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine CandidateGlobeNewswirePan-Ig and HBGA blocking antibody responses persisted to year 5 No adverse events deemed related to HIL-214 BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developi
- 4y agoHLVXHilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewswireInitiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212) Completed Upsized Initial Public Offering Raising $230 Million in Gross Proceeds BOSTON, June 08
- 4y agoHLVXHilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireBOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its initial public offering of 13,529,750 shares
- 4y agoHLVXHilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in InfantsGlobeNewswireBOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously announced Pha
- 4y agoHLVXHilleVax Announces Pricing of Upsized Initial Public OfferingGlobeNewswireBOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its upsized initial public offering of 11,765,0